Bildkälla: Stockfoto

ChromoGenics Q4 2023: Weak topline and higher costs, but the order pipeline looks good - Redeye

Redeye comments on ChromoGenics Q4 2023 report.

Börsvärldens nyhetsbrev
ANNONSER